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Abstract 
Background: Dysregulation of miRNAs that can act as tumor suppressors or oncogenes can result in tumorigenesis. 
Previously we demonstrated that miR-199b was significantly downregulated in acute myeloid leukemia (AML) and 
targets podocalyxin and discoidin domain receptor 1. Herein we investigated the functional role of miR-199b in AML 
and its prognostic implications.
Methods: Major approaches include transduction of hematopoietic stem cells and bone marrow transplantation, 
analyses of blood lineages, histone deacetylases (HDAC) inhibitors, and molecular and clinical data analyses of AML 
patients using The Cancer Genome Atlas (TCGA).
Results: We first examined the relative miR-199b expression in steady state hematopoiesis and showed CD33+ 
myeloid progenitors had the highest miR-199b expression. Further, silencing of miR-199b in CD34+ cells resulted in 
significant increases in CFU-GM colonies. Via TCGA we analyzed the molecular and clinical characteristics of 166 AML 
cases to investigate a prognostic role for miR-199b. The Kaplan–Meier curves for high and low expression values of 
miR-199b and the observed distribution of miRNA expression revealed the highly expressed group had significantly 
better survival outcomes (p < 0.016, log rank test). Additionally, there was significant difference between miR-199b 
expression across the AML subtypes with particularly low expression found in the FAB-M5 subtype. Furthermore, 
FAB-M5 subtype showed a poor prognosis with a 1-year survival rate of only 25 %, compared with 51 % survival in the 
overall sample (p < 0.024). Furthermore, significant inverse correlation of HoxA7 and HoxB6 expression with miR-199b 
was observed in FAB-M5 AML patients. Molecular mutations were analyzed among miR-199b high and low AML cases. 
Significant correlations in terms of association and survival outcomes were observed for NPMc and IDH1 mutations. 
Treatment of THP-1 cells (represents M5-subtype) with HDAC inhibitors AR-42, Panobinostat, or Decitabine showed 
miR-199b expression was significantly elevated upon AR-42 and Panobinostat treatment. To further understand the 
hematopathological consequences of decreased miR-199b, we employed a bone-marrow transduce/transplant 
(BMT) mouse model. Interestingly, in vivo miR-199b silencing per-se in HSCs did not result in profound perturbations.
Conclusions: Loss of miR-199b can lead to myeloproliferation while HDAC inhibitors restore miR-199b expression 
and promote apoptosis. Low miR-199b in AML patients correlates with worse overall survival and has prognostic 
significance for FAB-M5 subtype.
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Background
Acute myeloid leukemia (AML) manifests a marked heter-
ogeneity in both response to therapy and patient survival, 
observations that likely reflect its varied pathogenesis 
[1]. Dysregulation of miRNAs that can act as tumor sup-
pressors or oncogenes can result in tumorigenesis. One 
miRNA of interest is human miR-199b-5p. Human miR-
199b-5p is located on chromosome 9 and is an intragenic 
miRNA encoded in the dynamin 1 (DNM1) gene, from the 
opposite strand in a 2.2 kb intronic region between exons 
14 and 15 (Fig. 1a). Mature 5p arm, encoded by hsa-miR-
199b, is evolutionarily conserved among several species. 
Transcription of miR-199b is predicted to be independ-
ent of its host gene, DNM1. Studies to date have demon-
strated that miR-199b targets nuclear kinase Dyrk1a and 
promotes calcineurin/NFAT signaling in cardiomyocytes. 
Suppression of miR-199b expression has been reported in 
hepatocellular carcinoma and predicted poor prognosis 
in this disease [2]. Further, miR-199b was demonstrated 
to target HIF-1alpha in hepatocarcinoma cells and pros-
tate cancer cells [2, 3]. miR-199b has also been showed to 
target HER2 in breast cancer cells [4]. Notably, a recent 
investigation revealed overexpression of miR-199b-5p in 
medulloblastoma cancer stem cells results in downregu-
lation of CD133+ tumor initiating cells and causes deple-
tion of the side population compartment of tumor stem 
cells via negative regulation of the Hes1-mediated Notch 
signaling pathway [5].
Previously, we demonstrated miR-199b was signifi-
cantly downregulated in AML and targets podocalyxin 
Fig. 1 Intronic miR-199b expression in steady state hematopoiesis and its myelopoietic and hematopoietic potential. a miR-199b’s location within 
the genome; intronic of the DNM1 gene. b Human primary BM CD34+, BM CD33+, PB monocytes, PB eosinophils, and PB basophils expression 
of miR-199b in steady state hematopoiesis. c Lentiviral particles for anti-Has-miR-199b-5p and control vector were used to transduce human BM 
derived CD34 + cells. Silencing of miR-199b levels were confirmed in HSCs post transduction via RT-qPCR. d Lentiviral particles for anti-hsa-miR-
199b-5p and scrambled/control vector were used to transduce human BM derived CD34 + cells. CFU-GM assay was performed and representative 
photomicrographs of the colonies are shown
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and discoidin domain receptor 1 (DDR1) to regulate 
migration [6]. Down-regulation of miR-199b has been 
strongly associated with imatinib drug resistance in 
9q34.1 deleted BCR/ABL positive CML patients [7]. 
Silencing of miR-199b has also been associated with 
acquired chemoresistance in ovarian cancer, possibly 
mediated via activation of JAG-Notch1 signaling path-
way [8]. Interestingly, successful delivery of miR-199b 
in tumorigenic cell lines via stable nucleic acid particles 
(SNALPs) lead to impaired cell proliferation, however, no 
apoptosis was observed [9]. MiR-199 locus has also been 
implicated in intracellular trafficking where miR-199b 
and miR-199a together has been demonstrated to con-
trol receptor-mediated endocytosis via inhibiting CLTC, 
Rab5A, LDLR and Cav-1 expression [10].
The cause of miR-199b-5p downregulation in AML 
has yet to be examined. Studies have revealed 20  % of 
individuals with AML harbor somatic mutations in 
DNMT3A and genome-wide sequencing approaches 
have strengthened the notion that AML can be classified 
on the basis of patterns of promoter methylation [11, 12]. 
We hypothesized that future investigations into the epi-
genetic status such as histone modification via histone 
deacetylases (HDACs) or DNA methylation of miR-199b-
5p’s promoter may further unravel the link between aber-
rant epigenetic regulation and subsequent pathogeneic 
consequences manifested via the dysregulated expression 
of miR-199b-5p’s target genes as in silico analysis shows 
five upstream CpG islands (data not shown). Further-
more, miR-199b expression in steady state hematopoiesis 
has yet to be analyzed.
By gaining better insight into miR-199b-5p’s expres-
sion in steady state hematopoiesis, we can investigate the 
prognositic consequences of miR-199b-5p’s loss in depth 
in AML as well as determine if it can become a therapeu-
tic target for specific subtypes of AML. Herein, we aim 
to determine the hematopoietic/myelopoietic conse-
quences of miR-199b silencing ex vivo and in vivo via BM 
transplantation approach, clinical significance especially 
prognostic significance in AML and epigenetic regulation 
of miR-199b-5p in AML to garner more insight into its 
therapeutic potential. Additionally, in vivo investigations 
involving combinatorial deletions of cooperative factors 
like NPM1 or IDH1/2 are required to determine if miR-
199b has leukemogenic potential. This will elucidate if 
loss of miR-199b-5p directly contributes to leukemogen-
esis or if it is better served as a diagnostic and prognostic 
marker.
Results and discussion
Previously, we demonstrated miR-199b-5p was downreg-
ulated in a subset of AML patients but didn’t have suffi-
cient clinical details about the patients to draw a distinct 
correlation to miR-199b expression and AML subtype or 
overall survival. Additionally, both miR-199b’s normal 
expression pattern in hematopoiesis and its regulation 
have yet to be examined. Our current studies investigate 
the role of miR-199b in normal hematopoiesis and AML 
utilizing both ex vivo and in vivo approaches and analyz-
ing prognostic data obtained from The Cancer Genome 
Atlas (TCGA) on miR-199b expression in AML patients.
miR‑199b in normal hematopoiesis
To begin, we examined relative miR-199b expression in 
steady state hematopoiesis and showed CD33+ myeloid 
progenitors had the highest miR-199b expression, which 
drops upon differentiation (Fig. 1b). To test if suppression 
of miR-199b results in myeloproliferation and HSC pro-
liferation, human bone marrow derived CD34+ cells were 
transduced with anti-miR-199b or control lentivirus a 
CFU assay respectively. Silencing of miR-199b expression 
was confirmed via RTqPCR (Fig. 1c). Further, a functional 
validation of miR-199b silencing was tested by examining 
the levels of HIF1-alpha, a known and validated target of 
miR-199b [2]. Transcript levels of HIF1-alpha were sig-
nificantly elevated in hCD34 cells expressing anti-miR-
199b (Additional file 1: Figure S1). At day 16, silencing of 
miR-199b in CD34+ cells resulted in significant increases 
in CFU-GM colonies strongly suggesting dysregulation 
of miR-199b expression has a role in myelopoiesis and 
may be leukemogenic (Fig. 1d). The relatively low values 
observed for CFU-GM is possibly arising from the usage 
of cryopreserved human BM CD34 cells rather than 
freshly isolated human BM cells [13]. Notably, colony 
assays were performed with BFU-E and CFU-E; however, 
miR-199b silencing did not affect erythroid prolifera-
tion (data not shown). Transcription factors like cKit and 
RUNX1, known regulators of HSCs and Sp1, a transcrip-
tion factor that regulates myelopoiesis, are conserva-
tive targets of miR-199b [14–16]. Silencing of miR-199b 
in AML may in part lead to perturbed myelopoiesis via 
selective lineage specific dysregulation of key factors that 
direct myelopoiesis.
Clinical implications of low‑miR‑199b in AML
In order to correlate miR-199b expression with clinical 
AML patient data to determine any prognostic role, we 
utilized the Cancer Genome Atlas (TCGA) to analyze 
the molecular and clinical characteristics of 166 AML 
cases. Kaplan–Meier curves for high and low expres-
sion of miR-199b along with the observed distribution of 
miRNA expression revealed the highly expressed group 
(>2000 reads per million miRNA mapped) showed sig-
nificantly better survival outcome (Fig.  2a, p  <  0.016, 
log rank test). In addition, miR-199b expression varied 
by cytogenetic risk category in the least squared mean 
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plot, with significantly higher miR-199b expression in 
the favorable category compared to the intermediate and 
poor categories combined (Fig.  2b, p  <  0.0001). There-
fore, low expression of mir-199b predicts worse survival 
outcome and higher cytogenetic risk in AML.
Additionally, there was a significant difference in miR-
199b expression across the AML FAB subtypes with par-
ticularly low numbers of miR-199b-low patients in the 
M5 subtype (Fig. 2c) as well as low expression in M5 sub-
type (Fig. 2d). Further, M5 subtype shows a poor progno-
sis with a one-year survival rate of only 25 %, compared 
with 51 % survival in the overall sample (p < 0.024 with 
a Chi squared goodness of fit test). With AML patients 
grouped into M5 versus other subtypes to look at the 
dichotomized miR-199b variable, we find all of the M5 
patients have low miR-199b expression (p  <  0.0001). 
Thus, it is possible low miR-199b expression is a potential 
reason for poor survival outcomes in this subtype, and 
targeted treatment may represent a personalized treat-
ment regime for this subtype. Interestingly, most of the 
analyzed M5 AML patients were cytogenetically normal 
(CN-AML); however, these patients exhibited molecular 
mutations (Additional file 2: Table S1).
Next, we attempted to determine the potential coop-
erative role of these associated molecular abnormalities 
(FLT3-ITD, IDH–R140, -R132, -R172, activating Ras, 
NMPc) among miR-199b high and low AML patients. 
Significant correlations in terms of association and sur-
vival outcomes were observed for NPM1 and IDH1 
mutations. Among n =  128 AML patients analyzed for 
miR-199b/NPM1, n  =  63 were miR-199b-high sam-
ples and, of these, n = 2 were positive for NPM1 muta-
tion. Importantly, of the n = 65 miR-199b-low samples, 
n  =  41 were positive for NPM1 mutation (Fig.  2d, left 
panel, Fisher p value  =  1.94e-08, odds ratio 19.6). For 
IDH1 mutation, among the n = 139 AML patients ana-
lyzed for miR-199b/IDH1, n  =  59 were miR-199b-high 
samples (with n = 5 positive for IDH1 mutation) whereas 
n =  80 were miR-199b-low samples (with n =  25 posi-
tive for IDH1 mutation) (Fig.  2d, right panel, Fisher p 
value  =  0.012, odds ratio 3.7). Having a better under-
standing of miR-199b’s regulation could provide insight 
into specific therapies for low-miR-199b AML cases. It is 
tempting to speculate that NPM1 or IDH1 mutation may 
play a cooperative role in miR-199b-low associated AML, 
which if proved can facilitate the exploration of combi-
natorial strategies with MLN9708, a recently discovered 
and therapeutically tested inhibitor of mutated NPM1 
in AML [17] or AGI-6780 [18] for IDH2R140Q. Inter-
estingly, miRNA expression analysis in AML patients 
expressing mutant NPM1 reveals significant alterations 
in expression profile of select miRNAs including miR-
199a compared to AML with wild type NPM1 [19].
Next, in order to identify the molecular mechanism 
that could mediate the poor survival outcome and sub-
type specificity associated with low miR-199b expression, 
we queried gene expression data for co-expressed genes. 
A large number of genes were significantly correlated or 
anti-correlated with miR-199b expression, with the most 
significant negatively correlated genes listed (Additional 
file 3: Table S2). Included in this list are a large number of 
transcription factors in the HOX family which have been 
previously implicated in leukemia [20], and two of which, 
HOXA7 and HOXB6, are known targets of miR-199b. 
Hox family of transcription factors have been shown to 
play critical regulatory roles during hematopoiesis and 
their aberrant expression results in hematological malig-
nancies [21]. To see if the pattern of expression by sub-
type is reversed (since these genes are anti-correlated or 
transcriptionally repressed by 199b), we performed an 
ANOVA of 199b expression by subtype and found that 
indeed the expression of these genes is highest in the M5 
subtype, where 199b expression is the lowest (see Fig. 3a, 
b). Importantly, HOXA7 and HOXB6 expression was sig-
nificantly elevated in miR-199b-low AML samples with 
FAB-M5 subtype (Fig. 3a, b), which increases the possi-
bilities of important transcription factors coming in the 
regulatory ambit of miR-199b in HSCs.
Epigenetic regulation of miR‑199b
Due to miR-199b significantly correlating with M5 sub-
type, M5 cell line THP-1 was utilized to determine the 
epigenetic regulation of miR-199b in AML. Epigenetic 
alterations such as histone modifications and DNA 
methylation have been shown to deregulate miRNA 
expression. One example is miR-193a being modified via 
HDACs and DNA methyltransferases (DNMTs) associ-
ated with methylation through AML1/ETO recruitment 
of these factors [22]. Therefore, utilizing HDAC inhibi-
tors and demethylating agents can identify methylation 
status and histone modifications of miR-199b’s promoter 
and potentially be utilized as therapeutics in low-miR-
199b AML cases.
Treatment of THP-1 cells (24  h) with AR-42 (HDAC 
inhibitor), Panobinostat (Pano, HDAC inhibitor), or 
Decitabine (DB, demethylating agent) showed miR-199b 
expression was significantly elevated upon AR-42 and 
Pano treatment (p < 0.0002 and p < 0.0001 respectively) 
(Fig. 4a). To determine the efficacy of these HDAC inhib-
itors, acetylation of histones were analyzed via Western 
blot analysis (Fig. 4b). Further, apoptosis via Annexin V 
staining was analyzed in AR-42 and Pano treated cells 
to determine the functionality of these treatments and 
showed a marked increase in apoptosis in both treat-
ments (Fig. 4c). Thus, epigenetic regulation of miR-199b 
appears to be via histone modification.
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Fig. 2 Clinical relevance of miR-199b-5p across AML subtypes. a Kaplan–Meier analysis of 166 AML patients from the TCGA database for high/low 
miR-199b expression and overall survival, p = 0.0164. b miR-199b cytogenetic risk for same patients set. c High/low miR-199b expression by FAB 
subtype in the same patients set. d Least squared means plot of 199b expression for different FAB subtypes using ANOVA (p < 0.0001). e miR-199b 
levels for n = 128 AML patients analyzed for miR-199b/NPM1 with n = 63 miR-199b-high samples, of which n = 2 were positive for NPM1 mutation, 
and n = 65 miR-199b-low samples of which n = 41 positive for NPM1 mutation (Fisher p value = 1.941e-08, odds ratio 19.6112) (left panel). miR-
199b levels for n = 139 patients with n = 59 miR-199b-high samples (of which n = 5 positive for IDH1 mutation) whereas n = 80 were miR-199b-
low samples with n = 25 positive for IDH1 mutation (Fisher p value = 0.01175, odds ratio 3.663005) (right panel)
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Taken together, our results demonstrate in vitro loss of 
miR-199b can lead to myeloproliferation and HSC pro-
liferation while HDAC inhibitors (AR-42 or Pano) can 
recover miR-199b expression and promote apoptosis in 
leukemic cells. Both AR-42 and Pano are both clinically 
relevant as both are in clinical trials. For example, AR-42 
is in one clinical trial in combination with DB for patients 
with AML (ClinicalTrials.gov identifier: NCT01798901). 
One supporting study for this trial may be when AML 
cells were treated with AR-42; it raises miR-29b expres-
sion and primes the cells for DB treatment to induce 
apoptosis [23]. A clinical trial is currently pairing Pano 
with routine therapies of idarubicin and cytarabine in 
AML patients over the age of 65 (ClinicalTrials.gov iden-
tifier: NCT00840346). Both of these inhibitors could be 
a mode of therapy for AML patients with low-miR-199b.
miR‑199b‑low transplanted mouse
To further understand the hematopathological conse-
quences of decreased miR-199b in the onset and devel-
opment of myeloid leukemia, we employed a transduce/
transplant mouse model (Fig.  5a). The Lin−Sca-1+Kit+ 
(LSK) population was isolated from Ly5.2 C57Bl6 mice; 
transduced with anti-miR-199b or control lentivirus, and, 
using RT-qPCR, we confirmed that miR-199b was indeed 
much lower in these LSK cells (Fig.  5b, left panel). The 
transplanted LSK cells into Ly5.1 recipient mice post sub-
lethal irradiation.
Once the transplantation’s efficacy was confirmed by 
Ly5.1 and Ly5.2 staining of peripheral blood (PB) via 
flow cytometry (Fig. 3b, right panel) we hoped to observe 
leukemia in these mice by performing blood analysis. 
This analysis began at 3.5  weeks post-transplantation 
and continued every 4–6  weeks afterward to assess the 
complete blood count and observe the mice for any 
potential distress (Fig.  5c–g). Short-term (3.5  weeks) 
PB analysis determined loss of miR-199b results in sig-
nificant increase of neutrophils that was significantly 
sustained until 8  weeks post-transplantation (Fig.  5d). 
By 20  weeks post-transplantation the neutrophil counts 
recovered completely until they rose significantly again 
at 26  weeks. Early on, this indicated loss of miR-199b 
expression in HSCs could have leukemic potential but the 
recovery and subsequent increase through the 26 weeks 
indicate that on a myeloid leukemia standpoint, miR-
199b may not itself be leukemogenic.
Again, it is possible miR-199b works cooperatively with 
other mutations, as we suggested previously with IDH1 
and NPM1 mutations. Since miR-199b expression is 
highest in CD33+ cells during steady state hematopoiesis, 
perhaps the loss of miR-199b needs to be at the CD33+ 
stage instead of the CD34+ stage to induce myeloid leu-
kemia. Nonetheless, we chose to assess the complete 
blood count to determine any additional patterns in the 
blood profile since miR-199b was silenced in the HSCs 
and could be affecting all blood types. We saw no signifi-
cant changes in monocytes or eosinophils across the time 
course in the mice (Fig.  5f, g). Surprisingly, the whole 
white blood cell (WBC) count saw significant increases 
at weeks 8, 16, and 20 where it peaked before it was no 
longer significant at week 26 (Fig. 5c).
These results interestingly, were mirrored by the lym-
phocyte counts, which do contribute a large number to 
the WBC count (Fig. 5e). From this we can conclude that 
there may be either an immune response to the low miR-
199b or low miR-199b may play an important role in not 
only myelopoiesis but also lymphopoiesis. An interesting 
avenue to investigate further may be miR-199b’s expres-
sion in different types of lymphocytic leukemia or lym-
phoma to see if miR-199b is implicated in these forms of 
blood cancers. miR-199b has yet to be linked to any lym-
phocytic leukemias or lymphomas but there is a report 
that links low miR-199a expression in primary CNS lym-
phoma cases [24] therefore with the sequence homol-
ogy between miR-199a and miR-199b, miR-199b could 
be dysregulated in lymphomas as well and should be 
assessed via the TCGA database. At 27 weeks we chose 
Fig. 3 Expression of HoxA7 and HoxB6 inversely correlates with miR-
199b levels in AML with FAB M5 subtype. a Least square (LS) means 
plots of conserved miR-199b target HOXA7 (ANOVA p < 0.0001) 
versus different AML FAB categories. ANOVA *p < 0.0001 b Least 
square (LS) means plot of conserved miR-199b target HOXB6 (ANOVA 
p < 0.0017) versus different AML FAB categories. ANOVA *p < 0.0017
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to follow-up with flow cytometry for B and T cell mark-
ers to see if a specific cell type was increasing the high 
lymphocyte counts. Unfortunately, at this point, there 
were no significant difference between control and low-
miR-199b mice for the B or T cells (Fig. 5h). This could 
have been due to the fact that the lymphocyte numbers 
peaked at week 20.
Conclusions
More targeted studies are needed to determine how 
low miR-199b in HSCs leads to a myeloproliferative 
phenotype. In summary, it appears miR-199b plays an 
important regulatory role in differentiation and HDAC 
inhibitors are able to rescue miR-199b expression. 
MiR-199b appears to be a promising prognostic marker 
for FAB-M5-AML and CN-AML with NPM1 muta-
tion. This association is correlated with relatively poor 
survival; furthermore, FAB-M5-AML also correlates 
with heightened HOXA7 and HOXB6 expression, two 
transcription factors known to be targets of miR-199b. 
Though our in vivo transplant mouse model showed only 
transient hematopoietic perturbations, it is possible miR-
199b works cooperatively with these other mutations as 
part of a two-hit model leading to AML. Further stud-
ies are underway to examine the miR-199b’s cooperativ-
ity, possibly with NPM1, and how this mechanistically 
results in myeloproliferation.
Fig. 4 HDAC inhibitors restore miR-199b-5p expression in THP-1 cells to induce apoptosis. a miR-199b expression in THP-1 cells upon 24 h treat-
ment with vehicle (DMSO), Decitabine (DB, 5uM), AR-42 (2uM), or Panobinostat (0.7uM) ****p < 0.0001. b Western blot for THP-1 cells treated with 
DMSO [27], Panobinostat [28] or AR-42 [29] blotted for acetylated (Ac) and total histones H2A, H2B, H3 and H4. c Apoptosis via Annexin V staining 
for the AR-42 and Panobinostat treated cells compared to DMSO treatment
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Methods
Primary cell and RNA samples
Primary human bone marrow (BM) CD34+, BM CD33+, 
PB monocytes, PB eosinophils, and PB basophils RNA was 
obtained from stem cell technologies for transcript analysis.
miRNA isolation, cDNA synthesis, and RT‑qPCR
In order to determine the relative expression of miR-
199b, miRNA was isolated from cells using miRCURY 
RNA Isolation Kit (Exiqon) following the manufac-
turer’s instructions. cDNA was made utilizing the 
Fig. 5 miR-199b silencing in vivo via a transduce and transplant approach. a Bone marrow transplant (BMT) approach schematic to delete miR-
199b in hematopoietic cells. Mice were treated with 5-flourouracil, LSK (Lin−Sca+Kit+) cells were obtained and silenced with an anti-miR-199b lenti-
virus. These cells were then transplanted in irradiated Ly5.1 mice. b Left panel: Lentiviral particles for anti-miR-199b-5p and control vector were used 
to transduce mouse HSCs. Silencing of miR-199b levels were confirmed in HSCs post transduction via RTqPCR. Right panel: Engraftment efficiencies 
post BMT were measured using staining for Ly5.2 versus Ly5.1 via flow cytometry. A representative flow cytometry data is shown from the analysis. 
c–g Peripheral blood analysis for control and low-miR-199b transplant mice (n = 5). h Flow cytometry of peripheral blood B (CD19 staining) and T 
(CD3 staining) cells in control and low-miR-199b transplant mice at 27 weeks
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Universal cDNA Synthesis Kit II (Exiqon) for miRNA. 
RT-qPCR was performed using the miRCURY LNA 
Universal RT microRNA PCR system (Exiqon) and 2X 
SYBR Green master mix (SYBR Green/Fluorescein, cat 
#330513, SA Biosciences) on the iQ-Cycler (Bio-Rad) 
with the following primers (Exiqon) for miRNA analy-
ses: hsa-miR-199b-5p LNA™ PCR primer set, UniRT 
(Mature sequence: CCCAGUGUUUAGACUAUCU-
GUUC) and Reference primer set: U6 snRNA (hsa, 
mmu, rno).
CD34 cell culture, lentiviral transduction, CFC assay 
and HSC proliferation assay
In order to assess colony forming capabilities in normal 
CD34+ cells with low-miR-199b we purchased CD34pos 
cells (Stem Cell Tech) and expanded in StemSpan SFEM 
(StemCell Tech) containing FLT3 (100  ng/mL), IL-3, 
IL-6 (10  ng/mL each), SCF (100  ng/mL) and 1  % pen/
strep (Invitrogen). Lentiviral particles for hsa-miR-199b 
were generated by cotransfecting pEZX-AM03 vector 
expressing anti-miR-199b-5p (from H1 promoter) and 
mCherry fluorescent protein (CMV promoter) into 293T 
cells with the Lenti-Pac HIV packaging mix. Lentivirus 
products were titrated by quantitative RT-PCR, which 
determines the copy number of viral genomic RNA 
(titer = 3.3 × 1010 copies/mL). Anti-miR-199b lentivirus 
particles at a multiplicity of infection (MOI) between 10 
and 15 were added to the CD34+ cells at 37 °C. For con-
trols, lentivirus particles expressing mCherry were used 
at similar MOIs. The cells were infected for 15 h and then 
recovered in culture medium. Integration sites were veri-
fied by ligation mediated-PCR (LM-PCR) and sequenc-
ing. Significant silencing (95 %) of miR-199b expression 
was confirmed via RT-qPCR analysis. For colony forming 
assays, cell suspensions of 2  ×  105 cells/mL were pre-
pared and 0.4 mL of cells was added to 4 mL MethoCult 
medium containing GM-CSF, SCF and IL-3. A 16-gauge 
blunt-end needle attached to a 5  mL syringe was used 
to dispense the cells and MethoCult medium into cul-
ture dishes (n = 3 in duplicates). CFU-GM colonies were 
counted with bright field and fluorescent microscopy 
16 days after the cells were plated.
The cancer genome atlas analysis
When analyzing miR-199b levels in AML patient sam-
ples, level 3 gene expression, microRNA expression, and 
clinical data for 200 AML patients were downloaded 
from the data portal for the Cancer Genome Atlas Pro-
ject (TCGA, http://www.cancergenome.nih.gov). 187 of 
these samples had IlluminaGA RNASeq data for micro-
RNA expression, 179 samples had IlluminaGA RNASeq 
data for gene expression, and 166 samples had non-
missing data for survival time, gene, and microRNA 
expression and were used in subsequent analyses. All 
analyses were performed in R version 3.0.1 using the 
RStudio environment.
Box plots and t tests were performed for the associa-
tion between high and low miRNA expression (dichoto-
mized 2000 reads per miRNA mapped for 199b) and gene 
expression for candidate genes using standard R pack-
ages, with log transformations performed for expression 
variables due to lack of normality of raw variables. In fit-
ting a Cox proportional hazards model to the continu-
ous miRNA expression level, a significant model is found 
(p < 0.021; check proportional hazards assumption) with 
a risk ratio of 0.3 (0.10, 0.84), reciprocal 3.32, over the 
range of miRNA expression seen in this cohort. Kaplan–
Meier curves were performed using the survival package 
in R (survfit and survdiff functions), with the log rank p 
value used for testing difference in survival curves over 
strata. Tests of association between dichotomized micro-
RNA expression and gene expression variables were per-
formed using a Fisher’s Exact test (fisher.test function in 
R).
Ethics, consent, and permissions
The TCGA studies were performed in accordance with 




THP-1 cell line was cultured in RPMI-1640 Medium with 
0.05  mM 2-mercaptoethanol, 10  % fetal bovine serum 
and 1× penicillin, streptomycin, fungizone.
Inhibitors
THP-1 cells were treated with vehicle (DMSO), 5  μM 
Decitabine (DB), 2  μM AR-42, or 0.7  μM Panobinostat 
for 24  h for miR-199b-5p expression studies, apoptosis 
analysis via Annexin V staining, and protein expression 
via Western blot analysis.
Western blot
THP-1 cells with indicated treatments were lysed in 
M-PER mammalian protein extraction lysis buffer 
(Thermo Scientific, Cat #78501) containing Halt pro-
tease and phosphatase inhibitor cocktail (Thermo Sci-
entific, Cat #78442) and cleared lysates were assayed for 
protein content, denatured, electrophoresed, transferred 
to PVDF membranes, blocked and probed with the indi-
cated antibodies. Primary antibodies for both acetylated 
and total Histones H2A, H2B, H3, and H4 as well as beta-
tubulin were obtained from cell signaling. HRP-conju-
gated antibodies and ECL reagents were as described 
previously [26].
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Annexin V staining via flow cytometry
To analyze cell death, cells were stained with Annexin 
V (BD Pharmingen) and Propidium Iodide (invitrogen). 
Prior to staining, cells were washed with PBS and resus-
pended in 1× Annexin V binding buffer (BD Biosciences) 
and staining was performed by manufacturers instruc-
tions. After incubation, samples were analyzed via flow 
cytometry on the FACS Caliber (BD Biosciences).
Isolation and transduction of HSC with anti‑miR‑199b
In order to assess the effect of low-miR-199b in vivo, LSK 
cells were taken from donor mice and transduced with 
anti-miR-199b before being transplanted into recipi-
ent mice. To achieve this bone marrow from C57BL6/J 
(Ly5.2) mice was obtained for transduction of HSCs. 
Prior to extracting bone marrow, mice received intra-
peritoneal injections on days 1, 3, and 5 with 5-fluo-
rouracil (75  mg/kg). On day 7 cells were extracted, the 
LSK (Lin−Sca+Kit+) cells were enriched via bead selec-
tion kits (Stem Cell Technologies) and maintained in 
culture conditions. Anti-miR-199b lentivirus particles 
at a MOI between 10 and 15 were added to the cells at 
37  °C on Retronectin coated plates per manufacturers 
instructions. For controls, lentivirus particles express-
ing mCherry were used at similar MOIs. The cells were 
infected for 48 h and then recovered in culture medium 
before transplantation. Significant silencing (95  %) 
of miR-199b expression was confirmed via RT-qPCR 
analysis.
Bone marrow transplantations (BMT)
Control and anti-miR-199b transduced donor bone mar-
row (methods mentioned above) cells at 5  ×  105 cells 
were transplanted via retro-orbital injection into irradi-
ated B6 Ptprca (Ly5.1) recipients who underwent radia-
tion (450 cGy at 4 and 1  h before transplantation) to 
deplete their bone marrow. To confirm transplantation 
was effective, Ly5.1 and Ly5.2 staining was analyzed on 
PB via flow cytometry (see below).
Flow cytometry
Upon red cell lysis, cells were incubated with Ly5.1 and 
Ly5.2 antibodies (BD Biosciences) for 30  min to deter-
mine transplant efficiency. For B (CD19) and T (CD3) 
cell staining, similar methods were employed. Follow-
ing incubation, cells were washed and re-suspended in 
500 μL of PBS and analyzed on flow using FACScalibur 
(BD Biosciences).
Procyte blood analysis
A PB profile of transplanted miR-199b-low mice was 
completed at 3.5, 8, 12, 16, 20 and 26 weeks post-trans-
plantation. Mice were first anesthetized with isoflurane. 
Blood was collected using retro-orbital eye bleeding with 
heparinized capillary tubes to obtain 50–75 μL of blood. 
This blood was then analyzed on the ProCyte Dx Hema-
tology Analyzer (IDEXX) for a complete blood count 
profile output.
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